Hepatectomy in patients with inherited blood coagulation disorders can be safely performed with adequate coagulation factor replacement
Hepatectomy in patients with inherited blood coagulation disorders can be safely performed with adequate coagulation factor replacement
复制标题
遗传性凝血障碍患者可以安全地进行肝切除术,并补充足够的凝血因子
DOI:
10.1111/hae.13759
复制
发表时间:
2019
期刊:
影响因子:
3.9
通讯作者:
Halkic Nermin
中科院分区:
文献类型:
--
作者:
Kobayashi Kosuke;Kokudo Takashi;Yamaguchi Takamune;Shirata Chikara;Uldry Emilie;Akamatsu Nobuhisa;Arita Junichi;Kaneko Junichi;Yasumoto Atsushi;Demartines Nicolas;Hasegawa Kiyoshi;Halkic Nermin
BackgroundHaemophilia and von Willebrand disease (VWD) are common inherited bleeding disorders. Although patients with haemophilia or VWD have a high risk of hepatitis virus infection and hepatocellular carcinoma (HCC), little is known about the safety of liver resection in these patients.MethodsFrom 2006 to 2016, there were seven hepatectomies with haemophilia A and three hepatectomies with VWD for malignant liver tumours at tertiary care hospitals in Japan and Switzerland. To evaluate the safety of hepatectomy in the blood coagulation disorder group (BD group), short‐term outcomes in these patients were compared with 20 hepatectomies (non‐BD group) for HCC, matched to a 2:1, operative procedure, period and background liver.ResultsTen liver resections were performed in patients with haemophilia or VWD with administration of recombinant FVIII or VWF concentrate. Comparison of the BD vs non‐BD group revealed no significant differences in the operative time (327 vs 407 minutes,P= 0.359), estimated blood loss (730 vs 820 mL,P= 0.748), red blood cell transfusion rate (10.0% vs 5.0%,P= 0.605), major complication rate (Clavien‐Dindo grade III or IV) (10.0% vs 5.0%,P= 0.605) or mortality rate (0% vs 0%,P> 0.999). Additionally, the length of the postoperative hospital stay was similar between the two groups (13 vs 14 days,P= 0.296).ConclusionLiver resection for treatment of HCC in patients with haemophilia or VWD can be safely performed through an appropriate perioperative administration protocol of coagulation factors.
登录
查看更多内容
影响因子:
10.7
作者:
V. Gerling;J. Lahpor;W. Buhre
通讯作者:
W. Buhre
影响因子:
3.2
作者:
Kelly L. Vanderhave;M. Caird;M. Hake;R. Hensinger;A. Urquhart;Selina R Silva;F. Farley
通讯作者:
F. Farley
DOI:
--
发表时间:
1993
期刊:
Journal of acquired immune deficiency syndromes
影响因子:
--
作者:
Eyster,ME;Diamondstone,LS;Lien,JM;Ehmann,WC;Quan,S;Goedert,JJ
通讯作者:
Goedert,JJ
DOI:
10.1002/jhbp.142
发表时间:
2014
期刊:
Journal of Hepato‐Biliary‐Pancreatic Sciences
影响因子:
--
作者:
Yoshikuni Inokawa;H. Sugimoto;M. Kanda;S. Yamada;T. Fujii;S. Nomoto;S. Takeda;N. Suzuki;T. Matsushita;Y. Kodera
通讯作者:
Y. Kodera
影响因子:
7.5
作者:
Pasca, Samantha;Milan, Marta;Zanon, Ezio
通讯作者:
Zanon, Ezio